Fig 3.

Viability of leukaemia‐propagating cells following B‐cell lymphoma‐2 (BCL‐2) inhibitor treatment. (A) B‐cell precursor (BCP) acute lympohoblastic leukaemia (ALL) cells from six cases (pts. 9, 11, 14, 15, 19, 20) were sorted into four subpopulations using antibodies against CD34 and CD19. Each subpopulation was treated with navitoclax or venetoclax for up to 48 h and cell survival was measured by flow cytometry using annexin V and propidium iodide (PI). (B) Cells from six T‐cell (T‐)ALL cases (21, 25, 27–30) were sorted into four subpopulations using antibodies against CD34 and CD7 and treated with BCL‐2 inhibitors, as above. Unsorted cells from five T‐ALL cases were resistant to venetoclax (pts. 21, 25, 27, 28, 30) and 1one was sensitive (pt. 29, depicted separately). Viability is shown as mean ± SD across samples, expressed as a percentage of untreated controls. [Colour figure can be viewed at wileyonlinelibrary.com]